Preferred Dental Technologies Inc. announces it’s EAS product is being included in presentation Jun 23, 2017
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference Jun 17, 2017 Mining
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results May 19, 2017 Technology
Luminor Medical Technologies Acquiring Exclusive Canadian & Jamaican Licenses for Cannabis Products – Video Available on Investmentpitch.com May 12, 2017 Technology
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 12, 2017 Technology
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 9, 2017 Energy
